Regulatory Crossroads: The Future of Direct-to-Consumer Pharma Advertising
The debate over Direct-to-Consumer (DTC) pharmaceutical advertising is intensifying as U.S. regulators face mounting pressure to align with global standards. With the U.S. remaining one of only two nations allowing the practice, new legal and ethical challenges are questioning the impact of multi-billion dollar marketing budgets on drug pricing and patient safety.